Discoid lupus erythematosus DLE - Biotech, Pharma and Life Science Channel
Discoid lupus erythematosus (DLE) is a disease of the skin causing atrophy, scarring and photosensitivity. DLE affects between 17 and 48 per 100,000 people, occuring twice as often in women. The characteristic lesions are usually asymptomatic but they may present with mild pruritus or sometimes pain within the lesions. These lesions can be widespread, or localised to the head and neck.
About 90% of cases show a direct positive immunofluorescence in biopsies of lesions but this is not very specific. Approximately 20% of patients with DLE have a positive antinuclear antibody (ANA).
Treatment of DLE aims to improve the patient's appearance, to control existing lesions and limit scarring, and to prevent the development of further lesions. Lifestyle changes include avoiding sun exposure and smoking, and the drugs used are topical or intralesional steroids and antimalarials. Surgery may also be an option.
Source; Adapted from Patient UK
Add the Lupus News Channel to your RSS reader;
Follow the Lupus Twitter feed;
PubMed Articles
Trichinella infections in different host species of an endemic district of Serbia.
Trichinella infections are endemic in the Balkan region of Europe. Though trichinellosis and agents thereof are serious problems for human health and animal husbandry, only a limited number of Trichin...
A 35-year-old Japanese female patient with systemic lupus erythematosus (SLE) presented with fever, erythematous papules and nodules, and polyarthralgia. Skin biopsy of a nodule was compatible with Sw...
Systemic lupus erythematosus-related pancreatitis in children.
We report on three patients who developed four episodes of acute pancreatitis while their systemic lupus erythematosus was active and being treated with prednisolone. In all three, gastritis was first...
Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.
We describe a case of previously unreported autoimmune hepatitis and lupus-like syndrome induced by infliximab treatment for chronic plaque psoriasis. The condition resolved after withdrawal of inflix...
Tocilizumab is a highly effective therapeutic agent for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. Furthermore, a large amount of case study data reveals that to...
Decreased serum interleukin 27 in Brazilian systemic lupus erythematosus patients.
The immunological role of interleukin 27 has been reported in various inflammatory diseases, but its importance in systemic lupus erythematosus pathogenesis is not completely established. The aim of t...
Cyclophosphamide versus mycophenolate mofetil for initial treatment of lupus nephritis.
Progression of carotid atherosclerosis in patients with systemic lupus erythematosus.
The progression of carotid atherosclerosis in lupus patients is frequently encountered, and it is determined by both traditional and nontraditional risk factors. Of the 181 patients initially included...
The complement system is a component of the innate immune system. Its main function was initially believed to be limited to the recognition and elimination of pathogens through direct killing or stimu...
This study shows the diagnostic outcome of an APTT-based and two dRVVT-based commercial confirmatory integrated tests with the application of the recommendations by the Scientific and Standardization...
News Articles
Albany, NY, May 22, 2013 --(PR.com)-- Musculoskeletal diseases/disorders (MSDs) are diseases of muscles and related ligaments, and other connective tissues and bones. Some of the most common musculos...
ImmuPharma secures £50m to develop ex-Cephalon asset
ImmuPharma has secured a £50 million, five-year equity financing facility to fund its late stage lupus treatment. This will allow the company to complete Phase III development of Lupuzor. Lupuzor (p...
UPDATE: ImmuPharma strengthens hand with £50mln financing deal
ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune dise...
Lupus Support Group Meeting in Lapeer on June 11th
Lapeer, MI (PRWEB) May 21, 2013 The Michigan Lupus Foundation will be holding a lupus Support Group meeting in Lapeer on June 11th. Meeting Details: Tuesday, June 11th 7:00pm â 8:3...
SuppreMol Raises € 9.5 million in Extended Series D Financing Round
SuppreMol GmbH / SuppreMol Raises € 9.5 million in Extended Series D Financing Round . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this anno...
Running Out of Lupus Drug Options: A Case
Jonathan Kay reports the case of a woman who is proving to be intolerant of lupus treatments. Medscape Rheumatology
ImmuPharma agrees £50mln financing deal to take drug into final phase clinical trials
ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune dise...
Lupus Support Group Meeting in Lansing on June 10th
Lansing, MI (PRWEB) May 20, 2013 The Michigan Lupus Foundation will be holding a lupus support group meeting in Lansing on June 10th. Meeting Details: Monday, June 10th 6:30 p.m. â 8 p...
Edison Investment - Neovacs - Moving forward in rheumatoid arthritis
Neovacs intends to initiate a Phase IIb trial with its lead product TNFα-Kinoid in rheumatoid arthritis (RA). The strategy is designed to maintain momentum of the programme while it seeks a pa...
Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) announced today that the operational and financial results achieved thus far in 2013 encourage the Company to retain full year 2013 Grou...
Events
None
Companies
Ignyta, Inc., located in San Diego, California, is a personalized medicine company developing revolutionary new products and services to customize diagnosis and treatment of patie...
The International Society for Interferon and Cytokine Research (ISICR), based in Bethesda, Md., is a non-profit organization devoted to interferon, cytokine and chemokine r...
Lupus Foundation of America, Inc. (LFA)
The LFA is the foremost national nonprofit health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all people affec...
The LFA is the foremost national nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus, and providing support, services, and hope to all pe...
Lupus Foundation of America (LFA)
The Lupus Foundation of America (LFA) is the foremost national nonprofit organization dedicated to finding the causes of and cure for lupus, and providing support, services, and h...
ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop nov...
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-125, its novel tar...
Lupus Foundation of America, Inc.
Adamis Pharmaceuticals Corporation
La Jolla Pharmaceutical Company is a biopharmaceutical company. La Jolla had historically focused substantially all of its research, development and clinical efforts and financial...
Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, i...
Clinical Trials
Autoimmunity in Sisters of Lupus Patients
This study enrolled over 400 unaffected sisters of young women diagnosed with SLE. These unaffected sisters are being followed with an annual health questionnaire (CSQ) and blood sample.
The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring: 1. changes in brachial artery flow-mediated dilatati...
Several studies have shown that persons with systemic lupus erythematosus (SLE) have poor general health and a higher risk of heart attack and bone loss (osteoporosis) compared to the gene...
Although SLE and RA are correlated with genetic predisposing factors such as human leukocyte antigen (HLA) class II, both diseases and other genetic factors might have contributed to the d...
Triptorelin for Ovary Protection in Childhood Onset Lupus
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic...
Clinical Research Core Dental Screening Protocol
This study will screen patients for eligibility in studies sponsored by the Craniofacial Genetics Section (HCGS), the Clinical Research Core (CRC), and other branches located within the Na...
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic...
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
This study will examine a new approach to treating patient with severe systemic lupus erythematosus (SLE) that involves collecting stem cells (cells produced by the bone marrow that develo...
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodie...
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
High cholesterol levels are common in people with Systemic Lupus Erythematosus (SLE). Atorvastatin is a drug that reduces cholesterol levels. This study will test whether atorvastatin can...
Videos
Discoid Lupus Erythematosus - Clinical
Dr. Diane M. Hoss, MD discusses Discoid Lupus Erythematosus - Clinical. See more at http://www.dermnet.com PLEASE RATE AND COMMENT!!! Discoid lupus erythemat...
Medical and Biotech [MESH] Definitions
Procainamide
A derivative of PROCAINE with less CNS action. It also acts as a non-nucleoside inhibitor of DNA METHYLATION and has led to SYSTEMIC LUPUS ERYTHEMATOSUS.
Tuberculosis, Cutaneous
Tuberculosis of the skin. It includes scrofuloderma and tuberculid, but not LUPUS VULGARIS.
Glomerulonephritis, Membranoproliferative
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
Panniculitis, Lupus Erythematosus
A type of lupus erythematosus characterized by deep dermal or subcutaneous nodules, most often on the head, face, or upper arms. It is generally chronic and occurs most often in women between the ages of 20 and 45.
Hla-dr3 Antigen
Human immune-response, D-related antigen encoded by the D locus on chromosome 6 and found on lymphoid cells. It is in linkage disequilibrium with HLA-A1 and HLA-B8. The HLA-DR3 antigen is strongly associated with celiac disease, Grave's disease, dermatitis herpetiformis, early-age onset myasthenia gravis, systemic lupus erythematosus, juvenile diabetes, and opportunistic infections in AIDS.
